Referencias bibliográficas:

1. Gama, C. R. B., Gama, G. F., Lasmar, R. B., Fonseca, R. S., Guimarães, L. C., de Aquino, S., Geller, M., & Ribeiro, R. L. (2010). Clinical assessment of ethinylestradiol and cyproterone acetate in menstrual irregularities of hyper-androgenic origin. Revista Brasileira de Medicina, 67(9).
2. Bitzer, J., Römer, T., & Lopes da Silva Filho, A. (2017). The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms–a review. In European Journal of Contraception and Reproductive Health Care (Vol. 22, Issue 3). h-ttp-s:/-/doi-.org-/10.1080/13625187.2017.1317339
3. Fonseka, S., Wijeyaratne, C. N., Gawarammana, I. B., Kalupahana, N. S., Rosairo, S., Ratnatunga, N., & Kumarasiri, R. (2020). Effectiveness of Low-dose Ethinylestradiol/ Cyproterone Acetate and Ethinylestradiol/ Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-blind, Triple-dummy Study. Journal of Clinical and Aesthetic Dermatology, 13(7).
4. Ruan, X., Kubba, A., Aguilar, A., Mueck, A. O., Kubba, A., Aguilar, A., & Mueck, A. O. (2017). Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. In European Journal of Contraception and Reproductive Health Care (Vol. 22, Issue 3). h-ttp-s:/-/doi-.org-/10.1080/13625187.2017.1317735